← Back to Analyst Consensus 
BRNS Buy
Barinthus Biotherapeutics plc.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Nov 17, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $4 | 44% |
| Mar 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Jan 13, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $3 | 44% |
| Nov 19, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Nov 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Oct 1, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Sep 26, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Aug 13, 2024 | Alliance Global Partners | maintain | Buy → Buy | $9.5 | 41% |
| Aug 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Jun 13, 2024 | Barclays | maintain | — → Overweight | $3 | 53% |
| Jun 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| May 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Apr 22, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Apr 19, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Mar 21, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Nov 28, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Sep 25, 2023 | Alliance Global Partners | initiate | — → Buy | $12 | 41% |
| Sep 25, 2023 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $3.25 | 54% |
| Aug 18, 2023 | Morgan Stanley | maintain | Overweight → Overweight | $14 | 54% |
| Jun 13, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| May 16, 2023 | Morgan Stanley | maintain | Overweight → Overweight | $15 | 54% |
| Mar 29, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $15 | 44% |
| Mar 27, 2023 | HC Wainwright & Co. | maintain | — → Buy | $15 | 44% |
| Mar 21, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $20 | 44% |
| Aug 15, 2022 | Morgan Stanley | maintain | — → Overweight | $16 | 54% |
| Aug 11, 2022 | HC Wainwright & Co. | maintain | — → Buy | $20 | 44% |
| May 17, 2022 | Morgan Stanley | maintain | — → Overweight | $19 | 54% |
| May 13, 2022 | HC Wainwright & Co. | maintain | — → Buy | $22 | 44% |
| Dec 15, 2021 | HC Wainwright & Co. | maintain | — → Buy | $23 | 44% |
| May 25, 2021 | William Blair | initiate | — → Outperform | $0 | 47% |
| May 25, 2021 | Jefferies | initiate | — → Buy | $28 | 52% |
| May 25, 2021 | Morgan Stanley | initiate | — → Overweight | $22 | 54% |
| May 24, 2021 | HC Wainwright & Co. | initiate | — → Buy | $25 | 44% |
Price Target Trend
Apr 24, 2026 Oct 27, 2026
EPS Estimates
+1q —
0y —
+1y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days